A Phase I/II Study of Selinexor (SEL) with Sorafenib in Patients (pts) with Relapsed and/or Refractory (R/R) FLT3 Mutated Acute Myeloid Leukemia (AML)

被引：1

作者：

Daver, Naval ^{[1
]}

Assi, Rita ^{[1
]}

Ravandi, Farhad ^{[1
]}

Garcia-Manero, Guillermo ^{[1
]}

Jabbour, Elias ^{[1
]}

DiNardo, Courtney D. ^{[1
]}

Kadia, Tapan M. ^{[1
]}

Ning, Jing ^{[2
]}

Nogueras-Gonzalez, Graciela ^{[2
]}

Pierce, Sherry ^{[1
]}

Gombos, Dan ^{[3
]}

Komblau, Steven ^{[1
]}

Konopleva, Marina ^{[1
]}

Kelly, Mary ^{[1
]}

Borthakur, Gautam ^{[1
]}

Zhang, Weiguo ^{[1
]}

Cortes, Jorge ^{[1
]}

Kantarjian, Hagop ^{[1
]}

Andreeffl, Michael ^{[1
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA

[2] Univ Texas MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA

[3] Univ Texas MD Anderson Canc Ctr, Dept Ophthalmol, Houston, TX 77030 USA

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2017年 / 17卷 / 10期

关键词：

AML; selinexor; sorafenib; FLT3-mutation;

D O I：

10.1016/j.clml.2017.09.034

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

AML-025

引用

页码：S7 / S8

页数：2

共 50 条

[1] a Phase I/II Study of Selinexor (SEL) with Sorafenib in Patients (pts) with Relapsed and/or Refractory (R/R) FLT3 Mutated Acute Myeloid Leukemia (AML)
Daver, Naval
Assi, Rita
Garcia-Manero, Guillermo
Ravandi, Farhad
Borthakur, Gautam
Jabbour, Elias J.
DiNardo, Courtney D.
Kadia, Tapan
Ning, Jing
Gonzalez, Graciela Nogueras
Pierce, Sherry
Kelly, Mary
Zhang, Weiguo
Gombos, Dan
Kornblau, Steven
Konopleva, Marina
Cortes, Jorge E.
Kantarjian, Hagop M.
Andreeff, Michael
BLOOD, 2017, 130
[2] Final Results of Phase I/II Study of Selinexor (SEL) with Sorafenib in Patients (pts) with Relapsed and/or Refractory (R/R) FLT3 Mutated Acute Myeloid Leukemia (AML)
Daver, Naval G.
Assi, Rita
Kantarjian, Hagop M.
Cortes, Jorge E.
Ravandi, Farhad
Konopleva, Marina Y.
Kadia, Tapan M.
Borthakur, Gautam
Jabbour, Elias J.
DiNardo, Courtney D.
Velasquez, Michelle
Kelly, Mary
Ning, Jing
Gonzalez, Graciela M. Nogueras
Pierce, Sherry A.
Gombos, Dan
Estrov, Zeev E.
Kornblau, Steven M.
Zhang, Weiguo
Andreeff, Michael
BLOOD, 2018, 132
[3] A Phase I/II Study of Combination of ASTX727, Gilteritinib and Venetoclax in Patients with Relapsed/Refractory FLT3 Mutated Acute Myeloid Leukemia (AML) and Frontline FLT3 Mutated AML Patients Unfit for Chemotherapy
Ong, Faustine
Short, Nicholas
Daver, Naval
Kadia, Tapan M.
DiNardo, Courtney D.
Yilmaz, Musa
Alvarado, Yesid
Vaughan, Kenneth
Pierce, Sherry A.
Kantarjian, Hagop
Garcia-Manero, Guillermo
Ravandi, Farhad
BLOOD, 2022, 140 : 9029 - 9031
[4] A Phase I/II Study of Combination of ASTX727, Gilteritinib and Venetoclax in Patients with Relapsed/Refractory FLT3 Mutated Acute Myeloid Leukemia (AML)
Briski, Robert
Short, Nicholas J.
Daver, Naval
Kadia, Tapan M.
DiNardo, Courtney D.
Yilmaz, Musa
Valero, Yesid Alvarado
Vaughan, Kenneth
Pierce, Sherry
Montalbano, Kathryn
Mullin, Jillian
Kantarjian, Hagop M.
Garcia-Manero, Guillermo
Ravandi, Farhad
BLOOD, 2023, 142
[5] Results of a Phase II Study of Crenolanib in Relapsed/Refractory Acute Myeloid Leukemia Patients (Pts) with Activating FLT3 Mutations
Randhawa, Jasleen K.
Kantarjian, Hagop M.
Borthakur, Gautam
Thompson, Philip Alastair
Konopleva, Maria
Daver, Naval
Pemmaraju, Naveen
Jabbour, Elias
Kadia, Tapan M.
Estrov, Zeev
Ramachandran, Abhijit
Paradela, Jamil
Andreef, Michael
Levis, Mark
Ravandi, Farhad
Cortes, Jorge E.
BLOOD, 2014, 124 (21)
[6] Gilteritinib for the treatment of patients with FLT3 mutated relapsed or refractory acute myeloid leukemia
Wang, Eunice S.
EXPERT REVIEW OF PRECISION MEDICINE AND DRUG DEVELOPMENT, 2019, 4 (03): : 105 - 112
[7] First in Human (FIH) FLT3 and SYK Inhibitor HM43239 Shows Single Agent Activity in Patients (pts) with Relapsed or Refractory (R/R) FLT3 Mutated and Wild-Type Acute Myeloid Leukemia (AML)
Daver, Naval
Lee, Kyoo Hyung
Jung, Chul Won
Yoon, Sung-Soo
Arellano, Martha L.
Yoon, Jiyeon
Lee, Nora
Kim, Hyunjin
Lee, Jaeyeon
Jonas, Brian A.
Baek, Seungjae
BLOOD, 2021, 138
[8] Phase II study of cladribine, idarubicin, cytarabine (CLIA) plus gilteritinib in patients (pts) with FLT3 mutated acute myeloid leukemia (AML).
Abuasab, Tareq
Kantarjian, Hagop M.
Garcia-Manero, Guillermo
Bravo, Guillermo Montalban
Valero, Yesid Alvarado
Daver, Naval Guastad
Yilmaz, Musa
Pemmaraju, Naveen
Chien, Kelly Sharon
Kornblau, Steven Mitchell
Burger, Jan Andreas
Jain, Nitin
Islam, Rabiul
Dinardo, Courtney Denton
Borthakur, Gautam
Jabbour, Elias
Ravandi, Farhad
Kadia, Tapan M.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[9] Iadademstat in combination with gilteritinib for patients with mutated FLT3 relapsed/refractory acute myeloid leukemia
Fathi, Amir Tahmasb
Arevalo, Mabel
Gutierrez, Sonia
Molero, Antonieta
Sacilotto, Natalia
Limon, Ana E.
Faller, Douglas V.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[10] A Phase IB/II Study of Lirilumab with Azacytidine in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
Daver, Naval
Boddu, Prajwal
Ravandi, Farhad
Jabbour, Elias
Borthakur, Gautam
DiNardo, Courtney
Konopleva, Marina
Pemmaraju, Naveen
Kadia, Tapan
Jain, Nitin
Pierce, Sherry
Hussain, Nawar
Ning, Jing
Nogueras-Gonzalez, Graciela
Basu, Sreyashi
Cortes, Jorge
Sharma, Padmanee
Kantarjian, Hagop
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (10): : S6 - S7

← 1 2 3 4 5 →